Hepatic resection for the treatment of liver metastases in gastric carcinoma: review of the literature

Shirabe, Ken; Wakiyama, Shigeki; Gion, Tomonobu; Watanabe, Masayuki; Miyazaki, Michihiko; Yoshinaga, Keishi; Tokunaga, Masanori; Nagaie, Takashi

doi:10.1080/13651820500472168

Cited by 31 publications

(35 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Contraindications to hepatic resection are: previous extrahepatic disease; advanced lymph node involvement; and the inability to obtain liver R0 resection [17,18]. In the present study, the survival curves of N0, N1, and N2 cases were significantly higher than of N3 cases.…”

Section: Discussionsupporting

confidence: 52%

A Study of Gastric Cancer Cases with Liver Metastasis

Aoyagi

Kouhuji²,

Kizaki³

et al. 2013

J Gastrointest Dig Syst

View full text Add to dashboard Cite

The prognosis of gastric cancer patients with liver metastasis is very poor because many cases of gastric cancer with liver metastasis have multiple metastatic nodules in the liver and other non-curative factors, such as severe lymph node metastasis and/or peritoneal metastasis. The prognosis for gastric cancer patients with synchronous liver metastasis and the significance of hepatectomy including metachronous liver metastasis from gastric cancer in Kurume University Hospital are reported. Methods:A total of 77 gastric cancer patients with synchronous liver metastasis were admitted between 1995 and 2010 to Kurume University Hospital. There were 17 hepatectomy cases (synchronous metastasis 12 cases, metachronous metastasis 5 cases) from 1984 to 2010.Results: With respect to prognostic factors for gastric cancer cases with liver metastasis, significant differences were observed for peritoneal metastasis, histology, lymph node metastasis, gastrectomy, systemic chemotherapy, the number of stage IV factors, the number of metastatic nodules (within 3), and intra-hepatic arterial infusion (HAI). Multivariate analysis showed that histology, chemotherapy, and HAI were independent prognostic factors. The number of metastatic nodules in all 17 hepatectomy cases was within 3. Three of five cases with hepatectomy for metachronous metastasis were alive more than 5 years after hepatectomy. On the prognosis of hepatectomy cases, there were significant differences for synchronous or metachronous metastasis, lymph node metastasis, the number of stage IV factors, and the stromal volume of the primary site. Conclusions:Multimodal treatment including HAI is considered effective for gastric cancer cases with liver metastasis. If patients have no stage IV factors except for H factor, and the number of metastatic nodules is within 3, hepatectomy is recommended, especially for patients with metachronous liver metastasis, medullary stromal volume type, and low-grade lymph node metastasis.

show abstract

Section: Discussionsupporting

confidence: 52%

A Study of Gastric Cancer Cases with Liver Metastasis

Aoyagi

Kouhuji²,

Kizaki³

et al. 2013

J Gastrointest Dig Syst

View full text Add to dashboard Cite

show abstract

“…We performed gastrectomy for patients with liver metastasis based on previous reports. 26,27 In brief, we performed gastrectomy for patients with a solitary liver metastasis who have no peritoneal dissemination. Metastasis occur through various steps including the so-called EMT, which is an important process during tumor progression and metastasis development that causes loss of cell adhesion and increased cell motility.…”

Section: Discussionmentioning

confidence: 99%

Role of ES Cell-Expressed Ras (ERas) in Tumorigenicity of Gastric Cancer

Kubota

Kataoka

Aoyama

et al. 2010

The American Journal of Pathology

View full text Add to dashboard Cite

ERas, a unique member of the Ras family, was initially found only in embryonic stem (ES) cells, where it plays a crucial role in the transformation of transplanted ES cells to teratomas. ERas is involved in ES cell survival, and unlike other Ras family members, is constitutively active without any mutations. The aim of this study was to investigate the expression and role of ERas in human gastric cancer. To test whether ERas played a significant role in human cancer cells, we examined its expression and function in gastric cancer. ERas was expressed in gastric cancer cell lines at different levels. Induction of ERas expression activated the phosphatidylinositol 3 kinase (PI3K)/Akt axis and then enhanced anchorage-independent growth and ERas knockdown by siRNA suppressed cell invasion. Immunohistochemical analyses revealed that ERas was expressed in 38.7% (55/142) of human gastric carcinoma tissues, and its expression was significantly associated with metastasis to the liver (P < 0.0001) and lymph nodes (P < 0.05). ERas up-regulated transcription regulatory factors including ZFHX1A, ZFHX1B, and TCF3, which repress Ecadherin. These data suggest that ERas is activated in a significant population of gastric cancer , where it may play a crucial role in gastric cancer cell survival and metastases to liver via down-regulation of E-cadherin.

show abstract

“…-A single-center study on the effects of concurrent involvedfield radiotherapy and XELOX on oligometastatic recurrence as opposed to chemotherapy alone [13]. The literature included in the current German Guideline [14] contains a systematic review by Shirabe et al [15], collecting small retrospective studies on resection of hepatic metastases of gastric cancer.…”

Section: Resultsmentioning

confidence: 99%

Oligometastatic Disease in Upper Gastrointestinal Cancer - How to Proceed

et al. 2017

View full text Add to dashboard Cite

Background: In the present study we review and discuss the current evidence and suggest how to proceed in the management of oligometastatic disease in upper gastrointestinal cancer. Methods: An electronic search of the PubMed database for relevant articles was performed. Results: Both the search for ‘oligometastasis', ‘oligometastases', ‘oligometastatic', ‘oligometastatic disease' as well as ‘esophageal' and ‘esophageal cancer' and the search for ‘oligometastasis', ‘oligometastases', ‘oligometastatic', ‘oligometastatic disease' as well as ‘gastric', ‘gastric cancer', ‘stomach', and ‘stomach cancer' yielded very few studies. Most data need to be extrapolated in general studies on oligometastatic diseases of different origins. No randomized controlled trial could be found. Conclusion: In the absence of data to formulate recommendations on how to proceed in the treatment of oligometastatic disease in upper gastrointestinal cancer, a more aggressive treatment of oligometastatic disease can be considered in patients whose tumors show a more favorable neoplastic behavior after the ‘test of time'. The RENAISSANCE study will certainly deliver important data regarding this aspect.

show abstract

Hepatic resection for the treatment of liver metastases in gastric carcinoma: review of the literature

Cited by 31 publications

References 14 publications

A Study of Gastric Cancer Cases with Liver Metastasis

A Study of Gastric Cancer Cases with Liver Metastasis

Role of ES Cell-Expressed Ras (ERas) in Tumorigenicity of Gastric Cancer

Oligometastatic Disease in Upper Gastrointestinal Cancer - How to Proceed

Contact Info

Product

Resources

About